Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obeldesivir - Gilead Sciences

Next Previous
Drug Profile

Obeldesivir - Gilead Sciences

Alternative Names: GS-5245; ODV - Gilead Sciences

Latest Information Update: 11 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Amines; Antivirals; Esters; Furans; Nitriles; Nucleosides; Propionic acids; Pyrroles; Small molecules; Triazenes; Triazines
  • Mechanism of Action RNA-dependent RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Respiratory syncytial virus infections
  • Preclinical Viral haemorrhagic fevers

Most Recent Events

  • 09 Jun 2025 GSK terminates phase-II clinical trials in Respiratory syncytial virus infections in USA (PO) due to sponsor decision and not due to any safety findings(NCT06585150)
  • 16 Apr 2025 Gilead Sciences terminates phase II trial in Respiratory syncytial virus infections (In infants, In children, In neonates) in USA and Japan (PO), due to sponsor decision and not due to safety findings (NCT06784973)
  • 05 Mar 2025 Phase-II clinical trials in Respiratory syncytial virus infections (In children, In infants, In neonates) in Japan (PO) (NCT06784973)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top